Skip to main content
SpringerLink
Log in

Practice changing information in aggressive lymphoma, ASH 2015

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Out of the numerous papers dealing with lymphoma at the American Society of Hematology (ASH) 2015 meeting, three could change clinical practice. The DA-EPOCH-R regimen has improved the evidence for efficacy in Burkitt lymphoma. For lymphoproliferative disease after solid organ transplantation rituximab is a reasonable first-line treatment and nonresponders can be salvaged with R‑CHOP. For anaplastic large cell lymphoma the addition of etoposide to the CHOP regimen is an option. However, better regimens with new drugs are eagerly awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    Article  PubMed  Google Scholar 

  2. Fridrik MA. (editor) Burkitt and lymphoblastic lymphoma. Rickmansworth: ESMO Press s/s/media limited; 2012.

    Google Scholar 

  3. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Offner F, Samoilova O, Osmanov E, Eom H‑S, Topp MS, Raposo J, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, et al. Final results of a randomized phase 2 multicenter study of two Bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d’etude des Lymphomes de l’Adulte (GELA) study FL-05. Blood. 2010;116(21):768.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Center for Internal Medicine 3 – Hematology and Oncology, Kepler Hospital, Krankenhausstraße 9, 4021, Linz, Austria

    Michael A. Fridrik

Authors
  1. Michael A. Fridrik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Fridrik.

Ethics declarations

Conflict of interest

M. A. Fridrik is consultant for Roche and has received honoraria and other renumerations from the company.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fridrik, M.A. Practice changing information in aggressive lymphoma, ASH 2015. memo 9, 124–126 (2016). https://doi.org/10.1007/s12254-016-0271-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-016-0271-7

Keywords

Search

Navigation